Sernova awarded top-performing status on TSXV

Sernova Corp. ranks among top 50 performing companies on the 2022 TSX Venture list

LONDON-BASED SERNOVA CORP., a clinical-stage regenerative medicine and cell therapy therapeutics company focused on developing a potential ‘functional cure’ for type 1 diabetes and other chronic diseases, has been named as one of the top 50 performers on the TSX Venture Exchange for a second time.

The 2022 TSX Venture Top 50 is a ranking of top performers on the TSX Venture Exchange over the last year based on three equally weighted criteria: share price appreciation, average trading volume and market capitalization growth.

Story Continues Below

 

“We are honored by the TSX Venture Exchange recognition of Sernova as a 2022 Top 50 recipient company,” says Sernova CEO, Philip Toleikis. “Being awarded this title two years in a row is strong validation of our persistent dedication to increasing shareholder value as we continue to deliver on our strategic plan to build a leadership position in the regenerative medicine cell therapy therapeutics field.

“In 2022, we look forward to driving continued success through, evolving our clinical programs, further developing our pharmaceutical partnerships and by advancing our capital market initiatives.”

Story Continues Below

 

Click here to view a Q&A interview with Sernova CEO, Philip Toleikis

Headquartered at The Stiller Centre on Collip Circle, Sernova is developing regenerative medicine therapeutic technologies using a medical device ― its patented Cell Pouch system. Sernova’s approach is to provide a minimally invasive, retrievable, safe, organ-like environment for rapid engraftment and long-term survival of therapeutic cells as well as to avoid blood mediated inflammatory reactions and permit cell retrievability that cannot be achieved with the traditional portal vein transplantation.